GB0612540D0 - Galenical formulations of organic compounds - Google Patents

Galenical formulations of organic compounds

Info

Publication number
GB0612540D0
GB0612540D0 GBGB0612540.5A GB0612540A GB0612540D0 GB 0612540 D0 GB0612540 D0 GB 0612540D0 GB 0612540 A GB0612540 A GB 0612540A GB 0612540 D0 GB0612540 D0 GB 0612540D0
Authority
GB
United Kingdom
Prior art keywords
organic compounds
galenical formulations
galenical
formulations
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0612540.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36803824&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB0612540(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Priority to GBGB0612540.5A priority Critical patent/GB0612540D0/en
Publication of GB0612540D0 publication Critical patent/GB0612540D0/en
Priority to AU2007263261A priority patent/AU2007263261B2/en
Priority to US12/304,244 priority patent/US8618172B2/en
Priority to EP18177693.1A priority patent/EP3391878A1/en
Priority to MX2008016533A priority patent/MX2008016533A/es
Priority to ES07785832T priority patent/ES2704979T3/es
Priority to BRPI0713338-3A priority patent/BRPI0713338A2/pt
Priority to EP10191022A priority patent/EP2311439A1/en
Priority to JP2009515768A priority patent/JP5362556B2/ja
Priority to MYPI20084990A priority patent/MY146779A/en
Priority to RU2009101971/15A priority patent/RU2491058C2/ru
Priority to CA002654872A priority patent/CA2654872A1/en
Priority to CNA2007800225770A priority patent/CN101472566A/zh
Priority to PCT/EP2007/005476 priority patent/WO2007147596A1/en
Priority to KR1020087031081A priority patent/KR101442272B1/ko
Priority to EP07785832.2A priority patent/EP2034968B1/en
Priority to ARP070102734A priority patent/AR061565A1/es
Priority to NZ572937A priority patent/NZ572937A/en
Priority to PE2012000368A priority patent/PE20120990A1/es
Priority to TW096122538A priority patent/TWI457137B/zh
Priority to PE2007000804A priority patent/PE20080373A1/es
Priority to CL200701837A priority patent/CL2007001837A1/es
Priority to ZA200809773A priority patent/ZA200809773B/xx
Priority to IL195425A priority patent/IL195425A/en
Priority to EC2008008986A priority patent/ECSP088986A/es
Priority to GT200800297A priority patent/GT200800297A/es
Priority to TNP2008000528A priority patent/TNSN08528A1/en
Priority to MA31502A priority patent/MA30527B1/fr
Priority to NO20090262A priority patent/NO20090262L/no
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB0612540.5A 2006-06-23 2006-06-23 Galenical formulations of organic compounds Ceased GB0612540D0 (en)

Priority Applications (29)

Application Number Priority Date Filing Date Title
GBGB0612540.5A GB0612540D0 (en) 2006-06-23 2006-06-23 Galenical formulations of organic compounds
NZ572937A NZ572937A (en) 2006-06-23 2007-06-21 Solid oral dosage form of Aliskiren and hydrochlorothiazide which comprise a filler which is a mixture of wheat starch and lactose
RU2009101971/15A RU2491058C2 (ru) 2006-06-23 2007-06-21 Галеновый состав алискирена и гидрохлортиазида
PCT/EP2007/005476 WO2007147596A1 (en) 2006-06-23 2007-06-21 Galenical formulations of aliskiren and hydrochlorothiazide
ARP070102734A AR061565A1 (es) 2006-06-23 2007-06-21 Formulaciones galenicas de compuestos organicos
EP18177693.1A EP3391878A1 (en) 2006-06-23 2007-06-21 Galenical formulations of organic compounds
MX2008016533A MX2008016533A (es) 2006-06-23 2007-06-21 Formulaciones galenicas de alisquireno e hidroclorotiazida.
ES07785832T ES2704979T3 (es) 2006-06-23 2007-06-21 Formulaciones galénicas de aliskiren e hidroclorotiazida
BRPI0713338-3A BRPI0713338A2 (pt) 2006-06-23 2007-06-21 formulaÇÕes galÊnicas de compostos orgÂnicos
EP10191022A EP2311439A1 (en) 2006-06-23 2007-06-21 Galenical formulations of aliskiren and hydrochlorothiazide
JP2009515768A JP5362556B2 (ja) 2006-06-23 2007-06-21 アリスキレンおよびヒドロクロロチアジドのガレヌス製剤
MYPI20084990A MY146779A (en) 2006-06-23 2007-06-21 Galenical formulations of aliskiren and hydrochlorothiazide
US12/304,244 US8618172B2 (en) 2006-06-23 2007-06-21 Galenical formulations of organic compounds
CA002654872A CA2654872A1 (en) 2006-06-23 2007-06-21 Galenical formulations of aliskiren and hydrochlorothiazide
CNA2007800225770A CN101472566A (zh) 2006-06-23 2007-06-21 阿利吉仑和氢氯噻嗪的盖仑制剂
AU2007263261A AU2007263261B2 (en) 2006-06-23 2007-06-21 Galenical formulations of aliskiren and hydrochlorothiazide
KR1020087031081A KR101442272B1 (ko) 2006-06-23 2007-06-21 알리스키렌 및 히드로클로로티아지드의 갈레닉 제제
EP07785832.2A EP2034968B1 (en) 2006-06-23 2007-06-21 Galenical formulations of aliskiren and hydrochlorothiazide
PE2012000368A PE20120990A1 (es) 2006-06-23 2007-06-22 Formulaciones de alisquireno e hidroclorotiazida
CL200701837A CL2007001837A1 (es) 2006-06-23 2007-06-22 Forma de dosificacion oral solida que comprende alisquireno, hidroclorotiazida y un relleno hidrofilico; proceso de preparacion; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca congestiva, infarto de miocardio,
PE2007000804A PE20080373A1 (es) 2006-06-23 2007-06-22 Formulaciones de alisquireno e hidroclorotiazida
TW096122538A TWI457137B (zh) 2006-06-23 2007-06-22 有機化合物之蓋倫氏調配物
ZA200809773A ZA200809773B (en) 2006-06-23 2008-11-17 Galenical formulations of aliskiren and hydrochlorothiazide
IL195425A IL195425A (en) 2006-06-23 2008-11-20 Aliskiran and hydrochloric azide glenamic preparations
EC2008008986A ECSP088986A (es) 2006-06-23 2008-12-17 Formulaciones galénicas de alisquireno e hidroclorotiazida
GT200800297A GT200800297A (es) 2006-06-23 2008-12-17 Formulaciones galenicas de alisquireno e hidroclorotiazida
TNP2008000528A TNSN08528A1 (en) 2006-06-23 2008-12-19 Galenical formulations of aliskiren and hydrochlorothiazide
MA31502A MA30527B1 (fr) 2006-06-23 2008-12-24 Formes galeniques associant aliskirene et hydrochlorothiazide
NO20090262A NO20090262L (no) 2006-06-23 2009-01-16 Galeniske formuleringer av aliskiren og hydroklorotiazid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0612540.5A GB0612540D0 (en) 2006-06-23 2006-06-23 Galenical formulations of organic compounds

Publications (1)

Publication Number Publication Date
GB0612540D0 true GB0612540D0 (en) 2006-08-02

Family

ID=36803824

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0612540.5A Ceased GB0612540D0 (en) 2006-06-23 2006-06-23 Galenical formulations of organic compounds

Country Status (26)

Country Link
US (1) US8618172B2 (enExample)
EP (3) EP2034968B1 (enExample)
JP (1) JP5362556B2 (enExample)
KR (1) KR101442272B1 (enExample)
CN (1) CN101472566A (enExample)
AR (1) AR061565A1 (enExample)
AU (1) AU2007263261B2 (enExample)
BR (1) BRPI0713338A2 (enExample)
CA (1) CA2654872A1 (enExample)
CL (1) CL2007001837A1 (enExample)
EC (1) ECSP088986A (enExample)
ES (1) ES2704979T3 (enExample)
GB (1) GB0612540D0 (enExample)
GT (1) GT200800297A (enExample)
IL (1) IL195425A (enExample)
MA (1) MA30527B1 (enExample)
MX (1) MX2008016533A (enExample)
MY (1) MY146779A (enExample)
NO (1) NO20090262L (enExample)
NZ (1) NZ572937A (enExample)
PE (2) PE20080373A1 (enExample)
RU (1) RU2491058C2 (enExample)
TN (1) TNSN08528A1 (enExample)
TW (1) TWI457137B (enExample)
WO (1) WO2007147596A1 (enExample)
ZA (1) ZA200809773B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY148266A (en) * 2007-09-28 2013-03-29 Novartis Ag Galenical formulations of aliskiren
EP2143425A1 (de) * 2008-07-11 2010-01-13 Ratiopharm GmbH Direktverpresste Aliskiren-Tabletten
JP2010031006A (ja) * 2008-07-17 2010-02-12 Novartis Ag 有機化合物の使用
ES2365429B1 (es) 2010-03-05 2012-09-06 Universidad De Castilla De La Mancha Solucion para dialisis peritoneal
CN102626391B (zh) * 2012-04-19 2013-07-10 海南美兰史克制药有限公司 一种阿利克仑氢氯噻嗪药物组合物脂质体固体制剂
BR112015021002B8 (pt) * 2013-03-15 2023-03-28 Mallinckrodt Llc Forma de dosagem sólida farmacêutica compreendendo um ingrediente farmacêutico ativo

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US6010719A (en) 1997-09-16 2000-01-04 Universiteit Gent Freeze-dried disintegrating tablets
PE20001302A1 (es) * 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
IS1935B (is) * 2002-03-19 2004-06-16 Actavis Group Hf. Fósínópríl lyfjasamsetning
NZ536555A (en) * 2002-05-17 2007-03-30 Novartis Ag Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
BG65538B1 (bg) * 2002-07-05 2008-11-28 "Софарма" Ад Лекарствена форма на силимарин и метод за нейнотополучаване
WO2005077418A1 (en) * 2004-02-17 2005-08-25 Novartis Ag Combination of renin inhibitor and diuretics
PE20110121A1 (es) 2004-03-17 2011-02-28 Novartis Ag Composiciones farmaceuticas de aliskiren
EP1750862B1 (en) * 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
WO2006041763A1 (en) * 2004-10-04 2006-04-20 Novartis Ag Renin inhibitors for treating transplantation induced diseases
US8367105B2 (en) * 2004-11-10 2013-02-05 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
MY146830A (en) 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
MX2007013471A (es) * 2005-04-27 2008-01-22 Novartis Ag Metodos de tratamiento de aterosclerosis.
AU2006304836A1 (en) * 2005-10-21 2007-04-26 Novartis Ag Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent

Also Published As

Publication number Publication date
EP2034968A1 (en) 2009-03-18
TW200808358A (en) 2008-02-16
US8618172B2 (en) 2013-12-31
JP2009541239A (ja) 2009-11-26
AU2007263261B2 (en) 2011-07-14
PE20080373A1 (es) 2008-06-06
CL2007001837A1 (es) 2008-06-13
PE20120990A1 (es) 2012-08-16
KR20090021353A (ko) 2009-03-03
MY146779A (en) 2012-09-28
IL195425A (en) 2014-01-30
CN101472566A (zh) 2009-07-01
EP3391878A1 (en) 2018-10-24
ES2704979T3 (es) 2019-03-21
ECSP088986A (es) 2009-01-30
TWI457137B (zh) 2014-10-21
ZA200809773B (en) 2009-11-25
EP2034968B1 (en) 2018-10-31
NZ572937A (en) 2011-11-25
CA2654872A1 (en) 2007-12-27
BRPI0713338A2 (pt) 2012-03-06
GT200800297A (es) 2009-03-09
EP2311439A1 (en) 2011-04-20
AR061565A1 (es) 2008-09-03
IL195425A0 (en) 2009-08-03
US20090203679A1 (en) 2009-08-13
MA30527B1 (fr) 2009-06-01
MX2008016533A (es) 2009-01-19
JP5362556B2 (ja) 2013-12-11
RU2491058C2 (ru) 2013-08-27
AU2007263261A1 (en) 2007-12-27
NO20090262L (no) 2009-01-19
KR101442272B1 (ko) 2014-09-22
WO2007147596A1 (en) 2007-12-27
RU2009101971A (ru) 2010-07-27
TNSN08528A1 (en) 2010-04-14

Similar Documents

Publication Publication Date Title
GB0610242D0 (en) Organic compounds
GB0603684D0 (en) Organic compounds
GB0605691D0 (en) Organic Compounds
BRPI0715621A2 (pt) Formulações galênicas de compostos orgânicos
GB0606429D0 (en) Organic compounds
ZA201104489B (en) Galenic formulations of organic compounds
BRPI0817442A2 (pt) Formulações galênicas de composto orgânicos
GB0607953D0 (en) Organic compounds
GB0605689D0 (en) Organic compounds
GB0605688D0 (en) Organic compounds
GB0605120D0 (en) Organic Compounds
GB0604937D0 (en) Organic compounds
GB0612540D0 (en) Galenical formulations of organic compounds
BRPI0817586A2 (pt) Formulações galênicas de compostos orgânicos
GB0601406D0 (en) Organic Compounds
GB0601031D0 (en) Organic compounds
GB0602123D0 (en) Organic compounds
GB0601951D0 (en) Organic compounds
GB0603782D0 (en) Organic compounds
GB0624857D0 (en) Organic composition
GB0603880D0 (en) Organic compounds
GB0600238D0 (en) Organic compounds
GB0611064D0 (en) Organic compounds
GB0600618D0 (en) Organic compounds
GB0606202D0 (en) Organic compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)